Examples
Worked examples
- Is an instance
A Phase III oncology trial uses progression-free survival as its primary endpoint. Because the trial is open-label, the sponsor contracts an IRC vendor: independent radiologists, blinded to treatment arm and to the investigator's local read, apply RECIST 1.1 criteria to all scans to generate the endpoint dataset submitted to FDA alongside (not instead of) the local investigator assessment.
- Is an instance
A registrational trial measuring objective response rate has its local-site tumor-response calls audited by a central IRC as a sensitivity analysis, so reviewers can compare the concordance between local and independent reads and report any discordance to the regulator.
Counter-examples
Looks similar, but isn't
- Not an instance
A committee that unblinds interim efficacy and safety data during a trial and has the authority to recommend stopping the trial early for safety or futility is a Data Safety Monitoring Board (DSMB), not an IRC — its purpose is participant protection and trial-conduct oversight, it typically works unblinded, and it can halt the study. An IRC has no stopping authority, stays blinded to treatment assignment, and exists to produce an accurate, bias-minimized endpoint measurement, not a safety decision.
- Not an instance
A board that reviews a protocol before enrollment begins for participant risk, informed consent, and ethical acceptability is an Institutional Review Board (IRB) or Research Ethics Committee (REC), not an IRC — that review happens once, up front, and concerns human-subjects protection rather than re-measuring trial results.
- Not an instance
A panel that evaluates the scientific merit of a grant application to decide whether it gets funded (an NIH Study Section or a funder's Scientific Review Committee) is not an IRC — it reviews a proposal before a study exists, not endpoint data from a study already underway.
Editorial commentary
An Independent Review Committee (IRC) is an independent panel that re-assesses clinical trial efficacy endpoint data — most often medical imaging used to determine tumor response — against a predefined charter, without knowledge of treatment assignment or the local investigator’s own assessment. In oncology trials the same function is frequently called Blinded Independent Central Review (BICR); the two terms describe the same mechanism and are often used interchangeably in FDA guidance and trial literature.
Why it exists
Many registrational trials, particularly in oncology, cannot be fully blinded (for example, when treatment arms have visibly different administration routes or toxicity profiles). When a trial isn’t blinded, local investigators assessing whether a tumor has responded to treatment may be influenced, even unintentionally, by knowledge of which arm a patient is on. FDA guidance on clinical trial endpoints for cancer drug approval, and its draft guidance on imaging endpoint standards, addresses this by recommending or requiring a centralized, blinded re-read of imaging data by reviewers who have no knowledge of the treatment assignment or the site’s own conclusion.
How it differs from other review and oversight bodies
CASRAI’s dictionary already covers several other committees that oversee clinical and grant-funded research, and the naming overlap with “independent review” invites confusion. An IRC is functionally distinct from all of them:
- Institutional Review Board (IRB) / Research Ethics Committee (REC): reviews and approves a protocol before enrollment for participant risk, informed consent, and ethical acceptability, and continues ethical oversight through the study. It does not re-measure trial results.
- Data Safety Monitoring Board (DSMB): monitors unblinded interim safety and efficacy data during a trial and has authority to recommend stopping the trial early to protect participants. An IRC has no stopping authority and stays blinded.
- NIH Study Section / Scientific Review Committee: peer-reviews the scientific merit of a grant application before a study is funded and exists. An IRC reviews endpoint data from a study already underway.
In short: IRB/REC governs whether a study should ethically proceed; a DSMB governs whether a study should safely continue; a Scientific Review Committee/Study Section governs whether a study should be funded; an IRC governs whether a specific reported endpoint result is accurate and unbiased.
How it typically works
A sponsor (or an independent vendor engaged by the sponsor) recruits reviewers with relevant expertise — commonly radiologists for imaging-based oncology endpoints — who work under a written charter specifying the assessment criteria (such as RECIST 1.1 for solid tumor response), the read process (often independent double-reads with a third adjudicator for discordant cases), and blinding procedures that wall reviewers off from treatment assignment, local-site reads, and clinical outcome data. The resulting IRC-determined endpoint values, alongside the local investigator’s own assessment, are reported to the regulator as part of the marketing application.
For research administrators, the operational implication is mainly at trial start-up and budgeting: engaging an IRC/BICR vendor, drafting or reviewing the charter, and building the associated cost and timeline into the trial’s operational plan are separate workstreams from IRB submission and from DSMB charter development, even though all three can appear in the same protocol’s regulatory and oversight documentation.
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Independent Review Committee (IRC)"
vocab-term-identifier="https://casrai.org/dictionary/term/independent-review-committee-irc" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/independent-review-committee-irc",
"name": "Independent Review Committee (IRC)",
"identifier": "https://casrai.org/dictionary/term/independent-review-committee-irc",
"description": "An Independent Review Committee (IRC) — also called a Blinded Independent Central Review (BICR) in oncology trials — is a panel of qualified, external reviewers (typically radiologists or other specialists) who re-assess protocol-specified efficacy endpoint data, most commonly medical imaging, according to a predefined charter and standardized criteria (e.g., RECIST for tumor response). Reviewers work independently of the trial sponsor, investigators, and local site assessors, and are blinded to treatment assignment and to the local site's own read, to produce a bias-minimized, reproducible determination of endpoints such as objective response rate (ORR), progression-free survival (PFS), or time to progression (TTP). FDA guidance on cancer drug approval and on clinical trial imaging endpoints recommends or requires an IRC/BICR specifically when a trial is not fully blinded and endpoint assessment could otherwise be influenced by knowledge of treatment assignment.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
"url": "https://casrai.org/dictionary/term/independent-review-committee-irc",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-17T17:51:54",
"inLanguage": "en"
}
